Role of CYP3A in Oral Contraceptives Clearance.
作者信息
Zhang Nan, Shon Jihong, Kim Myong-Jin, Yu Chongwoo, Zhang Lei, Huang Shiew-Mei, Lee LaiMing, Tran Doanh, Li Li
机构信息
Office of Clinical Pharmacology (OCP), Office of Translational Sciences (OTS), Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring, Maryland, USA.
Oak Ridge Institute for Science and Education (ORISE), Tennessee, Oak Ridge, USA.
出版信息
Clin Transl Sci. 2018 May;11(3):251-260. doi: 10.1111/cts.12499. Epub 2017 Oct 6.
Abstract
摘要
相似文献
1
Role of CYP3A in Oral Contraceptives Clearance.细胞色素P450 3A在口服避孕药清除中的作用。
Clin Transl Sci. 2018 May;11(3):251-260. doi: 10.1111/cts.12499. Epub 2017 Oct 6.
2
4β-Hydroxycholesterol as an Endogenous Biomarker for CYP3A Activity: Literature Review and Critical Evaluation.4β-羟基胆固醇作为 CYP3A 活性的内源性生物标志物：文献综述与批判性评价。
J Clin Pharmacol. 2019 May;59(5):611-624. doi: 10.1002/jcph.1391. Epub 2019 Feb 12.
3
Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.使用基于生理的药代动力学建模与模拟评估考比替尼的细胞色素P450 3A4介导的药物相互作用潜力。
Clin Pharmacokinet. 2016 Nov;55(11):1435-1445. doi: 10.1007/s40262-016-0412-5.
4
Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.强效CYP3A抑制和诱导对口服蛋白酶体抑制剂伊沙佐米药代动力学的影响：晚期实体瘤或淋巴瘤患者的药物相互作用研究结果及基于生理的药代动力学分析
J Clin Pharmacol. 2018 Feb;58(2):180-192. doi: 10.1002/jcph.988. Epub 2017 Aug 11.
5
Evaluation of drug-drug interactions of pemigatinib in healthy participants.评估培米替尼在健康参与者中的药物相互作用。
Eur J Clin Pharmacol. 2021 Dec;77(12):1887-1897. doi: 10.1007/s00228-021-03184-z. Epub 2021 Jul 19.
6
Porcine cytochrome P450 3A: current status on expression and regulation.猪细胞色素 P450 3A：表达与调控的现状。
Arch Toxicol. 2020 Jun;94(6):1899-1914. doi: 10.1007/s00204-020-02710-9. Epub 2020 Mar 14.
7
Evaluation of Erythromycin as a Tool to Assess CYP3A Contribution of Low Clearance Compounds in a Long-Term Hepatocyte Culture.评价红霉素作为一种工具，用于评估长期肝细胞培养物中低清除率化合物的 CYP3A 贡献。
Drug Metab Dispos. 2020 Aug;48(8):690-697. doi: 10.1124/dmd.120.090951. Epub 2020 Jun 5.
8
Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor.利用转基因小鼠模型来了解MEK抑制剂考比替尼的口服处置及药物相互作用潜力。
Drug Metab Dispos. 2015 Jun;43(6):864-9. doi: 10.1124/dmd.115.063743. Epub 2015 Mar 26.
9
Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment.基于生理学的药代动力学模型预测 CYP3A 抑制剂/诱导剂对健康受试者和肝损伤受试者依斯巴伦诺内酯药代动力学的临床影响。
Eur J Clin Pharmacol. 2022 Jan;78(1):65-73. doi: 10.1007/s00228-021-03194-x. Epub 2021 Aug 20.
10
The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator.CYP3A 诱导和抑制对新型神经免疫调节剂拉喹莫德的药代动力学的影响。
Clin Pharmacol Drug Dev. 2020 Nov;9(8):1015-1024. doi: 10.1002/cpdd.785. Epub 2020 Apr 1.
引用本文的文献
1
First-in-Human Phase 1 Study to Evaluate the Clinical Pharmacology Properties of RBN-3143, a Novel Inhibitor of Mono-Adenosine Diphosphate Ribosyltransferase-PARP14.评估新型单磷酸腺苷二磷酸核糖基转移酶-PARP14抑制剂RBN-3143临床药理学特性的首次人体1期研究。
Clin Pharmacol Drug Dev. 2025 Jul;14(7):493-504. doi: 10.1002/cpdd.1539. Epub 2025 Apr 30.
2
Extensive modulation of the circulating blood proteome by hormonal contraceptive use across two population studies.两项人群研究表明，激素避孕的使用对循环血液蛋白质组有广泛调节作用。
Commun Med (Lond). 2025 Apr 22;5(1):131. doi: 10.1038/s43856-025-00856-0.
3
A preliminary exploration of liver microsomes and PBPK to uncover the impact of CYP3A4/5 and CYP2C19 on tacrolimus and voriconazole drug-drug interactions.对肝微粒体和生理药代动力学-药效学模型（PBPK）进行初步探索，以揭示细胞色素P450 3A4/5（CYP3A4/5）和细胞色素P450 2C19（CYP2C19）对他克莫司和伏立康唑药物相互作用的影响。
Sci Rep. 2025 Feb 21;15(1):6389. doi: 10.1038/s41598-025-91356-7.
4
17α-Ethynylestradiol and Levonorgestrel Exposure of Rainbow Trout RTL-W1 Cells at 18 °C and 21 °C Mainly Reveals Thermal Tolerance, Absence of Estrogenic Effects, and Progestin-Induced Upregulation of Detoxification Genes.17α-乙炔基雌二醇和左炔诺孕酮在 18°C 和 21°C 下对虹鳟 RTL-W1 细胞的暴露主要揭示了热耐受性、缺乏雌激素效应以及孕激素诱导的解毒基因上调。
Genes (Basel). 2024 Sep 10;15(9):1189. doi: 10.3390/genes15091189.
5
Physcion inhibition of CYP2C9, 2D6 and 3A4 in human liver microsomes.大黄酸抑制人肝微粒体中 CYP2C9、2D6 和 3A4。
Pharm Biol. 2024 Dec;62(1):207-213. doi: 10.1080/13880209.2024.2314089. Epub 2024 Feb 14.
6
Physiologically-based pharmacokinetic modeling of prominent oral contraceptive agents and applications in drug-drug interactions.基于生理学的主要口服避孕药的药代动力学模型及其在药物相互作用中的应用。
CPT Pharmacometrics Syst Pharmacol. 2024 Apr;13(4):563-575. doi: 10.1002/psp4.13101. Epub 2024 Jan 15.
7
Retrospective Analysis of Sugammadex Use in Adolescent Females on Progestin-Containing Contraceptives.孕激素避孕药使用者中少女使用罗库溴铵的回顾性分析。
J Pediatr Adolesc Gynecol. 2023 Oct;36(5):459-464. doi: 10.1016/j.jpag.2023.06.003. Epub 2023 Jun 19.
8
Combined Oral Contraceptives As Victims of Drug Interactions.口服避孕药作为药物相互作用的受害者。
Drug Metab Dispos. 2023 Jun;51(6):718-732. doi: 10.1124/dmd.122.000854. Epub 2023 Mar 24.
9
In Vitro Metabolism and CYP-Modulating Activity of Lavender Oil and Its Major Constituents.薰衣草油及其主要成分的体外代谢和 CYP 调节活性。
Molecules. 2023 Jan 12;28(2):755. doi: 10.3390/molecules28020755.
10
Quantifying the economic burden of unintended pregnancies due to drug-drug interactions with hormonal contraceptives from the United States payer perspective.从美国医保支付方的角度量化因激素避孕药药物相互作用导致意外怀孕的经济负担。
Gates Open Res. 2021 Nov 18;5:171. doi: 10.12688/gatesopenres.13430.1. eCollection 2021.
本文引用的文献
1
Metabolite Identification, Reaction Phenotyping, and Retrospective Drug-Drug Interaction Predictions of 17-Deacetylnorgestimate, the Active Component of the Oral Contraceptive Norgestimate.口服避孕药诺孕酯的活性成分17-去乙酰诺孕酯的代谢物鉴定、反应表型分析及回顾性药物相互作用预测
Drug Metab Dispos. 2017 Jun;45(6):676-685. doi: 10.1124/dmd.116.073940. Epub 2017 Mar 10.
2
Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol.细胞色素P450 3A4（CYP3A4）抑制剂酮康唑与激素屈螺酮联合炔雌醇或雌二醇之间的药代动力学相互作用。
Br J Clin Pharmacol. 2015 Dec;80(6):1399-410. doi: 10.1111/bcp.12745. Epub 2015 Oct 28.
3
Current contraceptive status among women aged 15-44: United States, 2011-2013.2011 - 2013年美国15 - 44岁女性的当前避孕状况
NCHS Data Brief. 2014 Dec(173):1-8.
4
Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: in vitro and in vivo correlation.丙型肝炎病毒蛋白酶抑制剂法达普韦与细胞色素P450酶的相互作用：体内外相关性
J Clin Pharmacol. 2015 Apr;55(4):467-77. doi: 10.1002/jcph.436. Epub 2015 Jan 14.
5
Effect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers.丙型肝炎病毒蛋白酶抑制剂法达普韦对健康女性志愿者中含炔雌醇和左炔诺孕酮的口服避孕药药代动力学的影响。
Antimicrob Agents Chemother. 2015 Jan;59(1):514-9. doi: 10.1128/AAC.03589-14. Epub 2014 Nov 10.
6
Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein.依伐卡托作为细胞色素P450和P-糖蛋白潜在抑制剂的临床药物相互作用评估。
J Clin Pharmacol. 2015 Jan;55(1):56-62. doi: 10.1002/jcph.377. Epub 2014 Aug 27.
7
Pharmacokinetic and pharmacodynamic interactions between the hepatitis C virus protease inhibitor, boceprevir, and the oral contraceptive ethinyl estradiol/norethindrone.丙型肝炎病毒蛋白酶抑制剂博赛泼维与口服避孕药炔雌醇/炔诺酮之间的药代动力学和药效学相互作用。
Eur J Clin Pharmacol. 2014 Sep;70(9):1107-13. doi: 10.1007/s00228-014-1711-0. Epub 2014 Jul 5.
8
In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia.体外OATP1B1和OATP1B3抑制作用与良性临床非结合性高胆红素血症的观察结果相关。
Xenobiotica. 2014 Mar;44(3):276-82. doi: 10.3109/00498254.2013.820006. Epub 2013 Jul 25.
9
Effect of netupitant, a highly selective NK₁ receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives.奈妥吡坦（一种高选择性 NK₁受体拮抗剂）对帕洛诺司琼药代动力学的影响，以及奈妥吡坦与帕洛诺司琼固定剂量组合与酮康唑、利福平及口服避孕药合用时的影响。
Support Care Cancer. 2013 Oct;21(10):2879-87. doi: 10.1007/s00520-013-1857-9. Epub 2013 Jun 11.
10
Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol/levonorgestrel oral contraceptive in healthy women.醋酸艾司利卡西平对健康女性中炔雌醇/左炔诺孕酮复方口服避孕药药代动力学的影响。
Epilepsy Res. 2013 Aug;105(3):368-76. doi: 10.1016/j.eplepsyres.2013.02.020. Epub 2013 Apr 6.
Zotero 插件